You just read:

Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

News provided by

Blueprint Medicines Corporation

May 15, 2020, 08:00 ET